
INFI
Healthcare · Biotechnology · $726,088 market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2023
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 1, 2023 | Time not confirmed | -0.12 | 0.00 | +100.0% |
| Aug 10, 2023 | After the close | -0.12 | -0.11 | +8.3% |
| May 9, 2023 | After the close | -0.10 | -0.12 | -20.0% |
| Mar 28, 2023 | After the close | -0.03 | -0.11 | -266.7% |
| Nov 14, 2022 | Before the open | -0.06 | -0.12 | -100.0% |
| Aug 9, 2022 | After the close | -0.15 | -0.13 | +13.3% |
| May 3, 2022 | After the close | -0.13 | -0.14 | -7.7% |
| Mar 29, 2022 | After the close | -0.13 | -0.13 | 0.0% |
| Nov 2, 2021 | After the close | -0.13 | -0.12 | +7.7% |
| Jul 27, 2021 | Before the open | -0.14 | -0.13 | +7.1% |
| May 13, 2021 | After the close | -0.12 | -0.15 | -25.0% |
| Mar 16, 2021 | After the close | -0.16 | -0.16 | 0.0% |
| Nov 9, 2020 | After the close | -0.16 | -0.16 |
Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative…
| 0.0% |
| Jul 30, 2020 | After the close | -0.19 | -0.16 | +15.8% |
| May 11, 2020 | Before the open | -0.13 | -0.19 | -46.2% |
| Mar 3, 2020 | After the close | -0.19 | -0.20 | -5.3% |
| Oct 30, 2019 | After the close | -0.10 | -0.20 | -100.0% |
| Jul 30, 2019 | Before the open | -0.07 | -0.18 | -157.1% |
| May 7, 2019 | After the close | -0.05 | -0.24 | -380.0% |
| Mar 14, 2019 | Before the open | -0.17 | -0.14 | +17.6% |
| Nov 5, 2018 | After the close | -0.15 | 0.23 | +253.3% |
| Aug 7, 2018 | After the close | -0.20 | -0.12 | +40.0% |
| May 8, 2018 | After the close | -0.18 | -0.18 | 0.0% |
| Mar 15, 2018 | After the close | -0.25 | -0.14 | +44.0% |